Critical questions for preclinical trials on safety and efficacy of vascular endothelial growth factor-based therapeutic angiogenesis for ischemic stroke

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 2, 2011, Pages 215-234

  Manoonkitiwongsa, P S ^a  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

Author keywords

Efficacy; Ischemic stroke; Preclinical studies; Safety; Stroke treatment; Therapeutic angiogenesis; Vascular endothelial growth factor

Indexed keywords

RECOMBINANT VASCULOTROPIN; VASCULOTROPIN;

AGE DISTRIBUTION; ANGIOGENESIS; ARTICLE; BRAIN ISCHEMIA; CHRONIC DISEASE; COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; HEMODYNAMICS; HUMAN; MONOTHERAPY; NERVE INJURY; NEUROPROTECTION; NONHUMAN; SEX DIFFERENCE; STEM CELL TRANSPLANTATION; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 79551657860     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152711794480447     Document Type: Article

References (315)

1. Wu, D. Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx., 2005, 2, 120-128.
2. Wahlgren, N.G.; Ahmed, N. Neuroprotection in cerebral ischaemia, facts and fancies - the need for new approaches. Cerebrovasc. Dis., 2004, 17, 153-166.
3. Diez-Tejedor, E.; Fuentes, B. Acute care in stroke, the importance of early intervention to achieve better brain protection. Cerebrovasc. Dis., 2004, 17, 130-137.
4. Broderick, J.P. Lecture, stroke therapy in the year 2025, burden, breakthroughs, and barriers to progress. Stroke, 2004, 35, 205-211.
5. Cheng, Y.D.; Al-Khoury, L.; Zivin, J.A. Neuroprotection for ischemic stroke, two decades of success and failure. NeuroRx., 2004, 1, 36-45.
6. Hinkle, J.L.; Bowman, L. Neuroprotection for ischemic stroke. J. Neurosci. Nursing, 2003, 35, 114-118.
7. Ovbiagele, B.; Kidwell, C.S.; Starkman, S.; Saver, J.L. Neuroprotective agents for the treatment of acute ischemic stroke. Curr. Neurol. Neurosci. Rep., 2003, 3, 9-20.
8. Röther, J. Neuroprotection does not work! Stroke, 2008, 39, 523-524.
9. Hussain, M.S.; Shuaib, A. Research into neuroprotection must continue. But with a different approach. Stroke, 2008, 39, 521-522.
10. Gladstone, D.J.; Black, S.E.; Hakim, A.M. Toward wisdom from failure, lessons from neuroprotective stroke trials and new therapeutic directions. Stroke, 2002, 33, 2123-2136.
11. Morgenstern, L.B. What have we learned from clinical neuroprotective trials? Neurology, 2001, 57, S45-S47.
12. Liebeskind, D.S.; Kasner, S.E. Neuroprotection for ischaemic stroke, an unattainable goal? CNS Drugs, 2001, 15, 165-174.
13. Parsons, A.A.; Irving, E.A.; Legos, J.J.; Lenhard, S.C.; Chandra, S.; Schaeffer, T.R.; Haimbach, R.E.; White, R.F.; Hunter, A.J.; Barone, F.C. Acute stroke therapy, translating preclinical neuroprotection to therapeutic reality. Curr. Opin. Investig. Drugs, 2000, 1, 452-463.
14. Segura, T.; Calleja, S.; Jordan, J. Recommendations and treatment strategies for the management of acute ischemic stroke. Expert Opin. Pharmacother., 2008, 9, 1071-1085.
15. Mehta, S.L.; Manhas, N.; Raghubir, R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res. Rev., 2007, 54, 34-66.
16. Curin, Y.; Ritz, M.F.; Andriantsitohaina, R. Cellular mechanisms of the protective effect of polyphenols on the neurovascular unit in strokes. Cardiovasc. Hematol. Agents Med. Chem., 2006, 4, 277-288.
17. Bazan, N.G.; Marcheselli, V.L.; Cole-Edwards, K. Brain response to injury and neurodegeneration, endogenous neuroprotective signaling. Ann. NY Acad. Sci., 2005, 1053, 137-147.
18. Ly, J.V.; Zavala, J.A.; Donnan, G.A. Neuroprotection and thrombolysis, combination therapy in acute ischaemic stroke. Expert Opin. Pharmacother., 2006, 7, 1571-1581.
19. Lapchak, P.A.; Zivin, J.A. Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits synergism with low-dose tissue plasminogen activator. Stroke, 2003, 34, 2013-2018.
20. Yepes, M.; Sandkvist, M.; Moore, E.G.; Bugge, T.H.; Strickland, D.K.; Lawrence, D.A. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J. Clin. Invest., 2003, 112, 1533-1540.
21. Cinelli, P.; Madani, R.; Tsuzuki, N.; Vallet, P.; Arras, M.; Zhao, C.N.; Osterwalder, T.; Rulicke, T.; Sonderegger, P. Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol. Cell Neurosci., 2001, 18, 443-457.
22. Yepes, M.; Sandkvist, M.; Wong, M.K.; Coleman, T.A.; Smith, E.; Cohan, S.L.; Lawrence, D.A. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood, 2000, 96, 569-576.
23. Nagai, N.; De, Mol. M.; Lijnen, H.R.; Carmeliet, P.; Collen, D. Role of plasminogen system components in focal cerebral ischemic infarction, a gene targeting and gene transfer study in mice. Circulation, 1999, 99, 2440-2444.
24. Wang, Y.F.; Tsirka, S.E.; Strickland, S.; Stieg, P.E.; Soriano, S.G.; Lipton, S.A. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med., 1998, 4, 228-231.
25. Tsirka, S.E.; Gualandris, A.; Amaral, D.G.; Strickland, S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature, 1995, 377, 340-344.
26. Benchenane, K.; Lopez-Atalaya, J.P.; Fernandez-Monreal, M.; Touzani, O.; Vivien, D. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci., 2004, 27, 155-160.
27. Kaur, J.; Zhao, Z.; Klein, G.M.; Lo, E.H.; Buchan, A.M. The neurotoxicity of tissue plasminogen activator? J. Cereb. Blood Flow Metab., 2004, 24, 945-963.
28. Lebeurrier, N.; Vivien, D.; Ali, C. The complexity of tissue-type plasminogen activator, can serine protease inhibitors help in stroke management? Expert Opin. Ther. Targets, 2004, 8, 309-320.
29. Kakuda, W.; Thijs, V.N.; Lansberg, M.G.; Bammer, R.; Wechsler, L.; Kemp, S.; Moseley, M.E.; Marks, M.P.; Albers, G.W. Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology, 2005, 65, 1175-1178.
30. Kahles, T.; Foerch, C.; Sitzer, M.; Schroeter, M.; Steinmetz, H.; Rami, A.; Neumann-Haefelin, T. Tissue plasminogen activator mediated blood-brain barrier damage in transient focal cerebral ischemia in rats, relevance of interactions between thrombotic material and thrombolytic agent. Vasc. Pharmacol., 2005, 43, 254-259.
31. Wang, Y.; Kilic, E.; Kilic, U.; Weber, B.; Bassetti, C.L.; Marti, H.H.; Hermann, D.M. VEGF overexpression induces postischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain, 2005, 128, 52-63.
32. Engelstein, E.; Margulies, J.; Jeret, J.S. Lack of t-PA use for acute ischemic stroke in a community hospital, high incidence of exclusion criteria. Am. J. Emerg. Med., 2000, 18, 257-260.
33. Chiu, D.; Krieger, D.; Villar-Cordova, C.; Kasner, S.E.; Morgenstern, L.B.; Bratina, P.L.; Yatsu, F.M.; Grotta, J.C. Intravenous tissue plasminogen activator for acute ischemic stroke, feasibility, safety, and efficacy in the first year of clinical practice. Stroke, 1998, 29, 18-22.
34. Krupinski, J.; Stroemer, P.; Slevin, M.; Marti, E.; Kumar, P.; Rubio, F. Three-dimensional structure and survival of newly formed blood vessels after focal cerebral ischemia. Neuroreport, 2003, 14, 1171-1176.
35. Sun, Y.; Jin, K.; Xie, L.; Childs, J.; Mao, X.O.; Logvinova, A.; Greenberg, D.A. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest., 2003, 111, 1843-1851.
36. Carmeliet, P.; Storkebaum, E. Vascular and neuronal effects of VEGF in the nervous system, implications for neurological disorders. Semin. Cell Dev. Biol., 2002, 13, 39-53.
37. Namiecinska, M.; Marciniak, K.; Nowak, J.Z. VEGF as an angiogenic, neurotropic, and neuroprotective factor. Postepy Hig. Med. Dosw., 2005, 59, 573-583.
38. Greenberg, D.A.; Jin, K. From angiogenesis to neuropathology. Nature, 2005, 438, 954-959.
39. Hayashi, T.; Noshita, N.; Sugawara, T.; Chan, P.H. Temporal profile of angiogenesis and expression of related genes in the brain after ischemia. J. Cereb. Blood Flow Metab., 2003, 23, 166-180.
40. Krupinski, J.; Kaluza, J.; Kumar, P.; Kumar, S.; Wang, J.M. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke, 1994, 25, 1794-1798.
41. Lovblad, K.O.; Baird, A.E. Actual diagnostic approach to the acute stroke patient. Eur. Radiol., 2006, 16, 1253-1269.
42. Baron, J.C. How healthy is the acutely reperfused ischemic penumbra? Cerebrovasc. Dis, 2005, 2, 25-31.
43. Maulaz, A.; Piechowski-Jozwiak, B.; Michel, P.; Bogousslavsky, J. Selecting patients for early stroke treatment with penumbra images. Cerebrovasc. Dis., 2005, 2, 19-24.
44. Alkawi, A.; Kirmani, J.F.; Janjua, N.; Khatri, I.; Ahmed, S.; Divani, A.A.; Qureshi, A.I. Advances in thrombolytics and mechanical devices for treatment of acute ischemic stroke. Neurol. Res., 2005, 27, S42-49.
45. Jahan, R. Hyperacute therapy of ischemic stroke, intravenous thrombolysis. Tech. Vasc. Interv. Radiol., 2005, 8, 81-86.
46. Xia, C.F.; Yin, H.; Yao, Y.Y.; Borlongan, C.V.; Chao, L.; Chao, J. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum. Gene. Ther., 2006, 17, 206-219.
47. Hu, X.; Zhou, D. Neovascularization after ischemic stroke. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, 2004, 21, 516-519.
48. Szpak, G.M.; Lechowicz, W.; Lewandowska, E.; Bertrand, E.; Wierzba-Bobrowicz, T.; Dymecki, J. Border zone neovascularization in cerebral ischemic infarct. Folia Neuropathol., 1999, 37, 264-268.
49. Zhang, Z.G.; Zhang, L.; Jiang, Q.; Zhang, R.; Davies, K.; Powers, C.; Bruggen, N.; Chopp, M. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J. Clin. Invest., 2000, 106, 829-838.
50. Jin, K.; Mao, X.O.; Greenberg, D.A. Vascular endothelial growth factor stimulates neurite outgrowth from cerebral cortical neurons via Rho kinase signaling. J. Neurobiol., 2006, 66, 236-242.
51. Zhang, Z.; Chopp, M. Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia. Trends Cardiovasc. Med., 2002, 12, 62-66.
52. Leventhal, C.; Rafii, S.; Rafii, D.; Shahar, A.; Goldman, S.A. Endothelial trophic support of neuronal production and recruitment from the adult mammalian subependyma. Mol. Cell Neurosci., 1999, 13, 450-464.
53. Muller-Ehmsen, J.; Schmidt, A.; Krausgrill, B.; Schwinger, R.H.; Bloch, W. Role of erythropoietin for angiogenesis and vasculogenesis, from embryonic development through adulthood. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, H331-H340.
54. Lu, D.; Mahmood, A.; Qu, C.; Goussev, A.; Schallert, T.; Chopp, M. Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J. Neurotrauma, 2005, 22, 1011-1017.
55. Maiese, K.; Li, F.; Chong, Z.Z. Erythropoietin in the brain, can the promise to protect be fulfilled? Trends Pharmacol. Sci., 2004, 25, 577-583.
56. Li, F.; Chong, Z.Z.; Maiese, K. Erythropoietin on a tightrope, balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals, 2004, 13, 265-289.
57. Ehrenreich, H.; Aust, C.; Krampe, H.; Jahn, H.; Jacob, S.; Herrmann, M.; Siren, A.L. Erythropoietin, novel approaches to neuroprotection in human brain disease. Metab. Brain Dis., 2004, 19, 195-206.
58. Lu, D.; Goussev, A.; Chen, J.; Pannu, P.; Li, Y.; Mahmood, A.; Chopp, M. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J. Neurotrauma, 2004, 21, 21-32.
59. Chen, X.; Katakowski, M.; Li, Y.; Lu, D.; Wang, L.; Zhang, L.; Chen, J.; Xu, Y.; Gautam, S.; Mahmood, A.; Chopp, M. Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts, growth factor production. J. Neurosci. Res., 2002, 69, 687-691.
60. Siren, A.L.; Knerlich, F.; Poser, W.; Gleiter, C.H.; Bruck, W.; Ehrenreich, H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol., 2001, 101, 271-276.
61. Tsukahara, T.; Yonekawa, Y.; Tanaka, K.; Ohara, O.; Wantanabe, S.; Kimura, T.; Nishijima, T.; Taniguchi, T. The role of brainderived neurotrophic factor in transient forebrain ischemia in the rat brain. Neurosurgery, 1994, 34, 323-331.
62. Shimohama, S.; Tamura, Y.; Akaike, A.; Tsukahara, T.; Ohara, O.; Watanabe, S.; Kimura, J. Brain-derived neurotrophic factor pretreatment exerts a partially protective effect against glutamateinduced neurotoxicity in cultured rat cortical neurons. Neurosci. Lett., 1993, 164, 55-58.
63. Shigeno, T.; Mima, T.; Takakura, K.; Graham, D.I.; Kato, G.; Hashimoto, Y.; Furukawa, S. Amelioration of delayed neuronal death in the hippocampus by nerve growth factor. J. Neurosci., 1991, 11, 2914-2919.
64. Gora-Kupilas, K.; Josko, J. The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol., 2005, 43, 31-39.
65. Ferrara, N. Vascular endothelial growth factor, basic science and clinical progress. Endocr. Rev., 2004, 25, 581-611.
66. Storkebaum, E.; Lambrechts, D.; Carmeliet, P. VEGF, once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays, 2004, 26, 943-954.
67. Rosenstein, J.M.; Krum, J.M. New roles for VEGF in nervous tissue--beyond blood vessels. Exp. Neurol., 2004, 187, 246-253.
68. Bates, D.O.; Harper, S.J. Regulation of vascular permeability by vascular endothelial growth factors. Vasc. Pharmacol., 2002, 39, 225-237.
69. Breier, G. Functions of the VEGF/VEGF receptor system in the vascular system. Semin. Thromb. Hemost., 2000, 26, 553-559.
70. Clauss, M. Molecular biology of the VEGF and the VEGF receptor family. Semin. Thromb. Hemost., 2000, 26, 561-569.
71. Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev., 1997, 18, 4-25.
72. Olsson, A.K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol., 2006, 7, 359-371.
73. Bacic, M.; Edwards, N.A.; Merrill, M.J. Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Growth Factors, 1995, 12, 11-15.
74. Hicklin, D.J.; Ellis, L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol., 2005, 23, 1011-1027.
75. Abumiya, T.; Lucero, J.; Heo, J.H.; Tagaya, M.; Koziol, J.A.; Copeland, B.R.; del Zoppo, G.J. Activated microvessels express vascular endothelial growth factor and integrin alpha(v)beta3 during focal cerebral ischemia. J. Cereb. Blood Flow Metab., 1999, 19, 1038-1050.
76. Marti, H.H.; Risau, W. Systemic hypoxia changes the organspecific distribution of vascular endothelial growth factor and its receptors. Proc. Natl. Acad. Sci. USA, 1998, 95, 15809-15814.
77. Monacci, W.T.; Merrill, M.J.; Oldfield, E.H. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am. J. Physiol., 1993, 264, C995-C1002.
78. Lennmyr, F.; Terent, A.; Syvanen, A.C.; Barbany, G. Vascular endothelial growth factor gene expression in middle cerebral artery occlusion in the rat. Acta Anaesthesiol. Scand., 2005, 49, 488-493.
79. Forsythe, J.A.; Jiang, B.H.; Iyer, N.V.; Agani, F.; Leung, S.W.; Koos, R.D.; Semenza, G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol., 1996, 16, 4604-4613.
80. Wang, X.; Tsuji, K.; Lee, S.R.; Ning, M.; Furie, K.L.; Buchan, A.M.; Lo, E.H. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke, 2004, 35, 2726-2730.
81. Hai, J.; Li, S.T.; Lin, Q.; Pan, Q.G.; Gao, F.; Ding, M.X. Vascular endothelial growth factor expression and angiogenesis induced by chronic cerebral hypoperfusion in rat brain. Neurosurgery, 2003, 53, 963-970.
82. Stowe, A.M.; Plautz, E.J.; Eisner-Janowicz, I.; Frost, S.B.; Barbay, S.; Zoubina, E.V.; Dancause, N.; Taylor, M.D.; Nudo, R.J. VEGF protein associates to neurons in remote regions following cortical infarct. J. Cereb. Blood Flow Metab., 2007, 27, 76-85.
83. Beck, H.; Plate, K.H. Angiogenesis after cerebral ischemia. Acta Neuropathol., 2009, 117, 481-496.
84. Carmeliet, P.; Ferreira, V.; Breier, G.; Pollefeyt, S.; Kieckens, L.; Gertsenstein, M.; Fahrig, M.; Vandenhoeck, A.; Harpal, K.; Eberhardt, C.; Declercq, C.; Pawling, J.; Moons, L.; Collen, D.; Risau, W.; Nagy, A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 1996, 380, 435-439.
85. Ferrara, N.; Carver-Moore, K.; Chen, H.; Dowd, M.; Lu, L.; O'Shea, K.S.; Powell-Braxton, L.; Hillan, K.J.; Moore, M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature, 1996, 380, 439-442.
86. Zhu, W.; Mao, Y.; Zhao, Y.; Zhou, L.F.; Wang, Y.; Zhu, J.H.; Zhu, Y.; Yang, G.Y. Transplantation of vascular endothelial growth factor-transfected neural stem cells into the rat brain provides neuroprotection after transient focal cerebral ischemia. Neurosurgery, 2005, 57, 325-333.
87. Chu, K.; Park, K.I.; Lee, S.T.; Jung, K.H.; Ko, S.Y.; Kang, L.; Sinn, D.I.; Lee, Y.S.; Kim, S.U.; Kim, M.; Roh, J.K. Combined treatment of vascular endothelial growth factor and human neural stem cells in experimental focal cerebral ischemia. Neurosci. Res., 2005, 53, 384-390.
88. Cao, L.; Jiao, X.; Zuzga, D.S.; Liu, Y.; Fong, D.M.; Young, D.; During, M.J. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat. Genet., 2004, 36, 827-835.
89. Yasuhara, T.; Shingo, T.; Date, I. The potential role of vascular endothelial growth factor in the central nervous system. Rev. Neurosci., 2004, 15, 293-307.
90. Krum, J.M.; Khaibullina, A. VEGF impedes revascularization and astroglial proliferation, roles for VEGF in repair. Exp. Neurol., 2003, 181, 241-257.
91. Bellomo, M.; Adamo, E.B.; Deodato, B.; Catania, M.A.; Mannucci, C.; Marini, H.; Marciano, M.C.; Marini, R.; Sapienza, S.; Giacca, M.; Caputi, A.P.; Squadrito, F.; Calapai, G. Enhancement of expression of vascular endothelial growth factor after adenoassociated virus gene transfer is associated with improvement of brain ischemia injury in the gerbil. Pharmacol. Res., 2003, 48, 309-317.
92. Ferrara, N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis, therapeutic implications. Semin. Oncol., 2002, 29, 10-14.
93. del Zoppo, G.J. Acute stroke--on the threshold of a therapy? N. Engl. J. Med., 1995, 333, 1632-1633.
94. Murphy, J. Pharmacological treatment of acute ischemic stroke. Crit. Care Nurs. Q., 2003, 26, 276-282.
95. Locatelli, F.; Bersano, A.; Ballabio, E.; Lanfranconi, S.; Papadimitriou, D.; Strazzer, S.; Bresolin, N.; Comi, G.P.; Corti, Stem cell therapy in stroke. S. Cell Mol. Life Sci., 2009, 66,757-772.
96. Gerber, H.P.; McMurtrey, A.; Kowalski, J.; Yan, M.; Keyt, B.A.; Dixit, V.; Ferrara, N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'- kinase/Akt signal transduction pathway. J. Biol. Chem., 1998, 273, 30336-30343.
97. Jin, K.; Mao, X.O.; Batteur, S.P.; McEachron, E.; Leahy, A.; Greenberg, DA. Caspase-3 and the regulation of hypoxic neuronal death by vascular endothelial growth factor. Neuroscience, 2001, 108, 351-358.
98. Qiu, M.H.; Zhang, R.; Sun, F.Y. Enhancement of ischemia-induced tyrosine phosphorylation of Kv1.2 by vascular endothelial growth factor via activation of phosphatidylinositol 3-kinase. J. Neurochem., 2003, 87, 1509-1517.
99. Xu, J.Y.; Zheng, P.; Shen, D.H.; Yang, S.Z.; Zhang, L.M.; Huang, Y.L.; Sun, F.Y. Vascular endothelial growth factor inhibits outward delayedrectifier potassium currents in acutely isolated hippocampal neurons. Neuroscience, 2003, 118, 59-67.
100. Beierle, E.A.; Nagaram, A.; Dai, W.; Iyengar, M.; Chen, M.K. VEGF-mediated survivin expression in neuroblastoma cells. J. Surg. Res., 2005, 127, 21-28.
101. Tolosa, L.; Mir, M.; Asensio, V.J.; Olmos, G.; Llado, J. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. J. Neurochem., 2008, 105, 1080-1090.
102. Stewart, D.J.; Kutryk, M.J.; Fitchett, D.; Freeman, M.; Camack, N.; Su, Y.; Della Siega, A.; Bilodeau, L.; Burton, J.R.; Proulx, G.; Radhakrishnan, S. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease, results of the NORTHERN trial. Mol. Ther., 2009, 17, 1109-1115.
103. van Weel, V.; van Tongeren, R.B.; van Hinsbergh, V.W.; van Bockel, J.H.; Quax, P.H. Vascular growth in ischemic limbs, a review of mechanisms and possible therapeutic stimulation. Ann. Vasc. Surg., 2008, 22, 582-597.
104. Jiang, H.; Zhang, T.; Sun, X. Vascular endothelial growth factor gene delivery by magnetic DNA nanospheres ameliorates limb ischemia in rabbits. J. Surg. Res., 2005, 126, 48-54.
105. Matsumoto, R.; Omura, T.; Yoshiyama, M.; Hayashi, T.; Inamoto, S.; Koh, K.R.; Ohta, K.; Izumi, Y.; Nakamura, Y.; Akioka, K.; Kitaura, Y.; Takeuchi, K.; Yoshikawa, J. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1168-1173.
106. Kim, H.J.; Jang, S.Y.; Park, J.I.; Byun, J.; Kim, D.I.; Do, Y.S.; Kim, J.M.; Kim, S.; Kim, B.M.; Kim, W.B.; Kim, D.K. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp. Mol. Med., 2004, 36, 336-344.
107. Hughes, G.C.; Biswas, S.S.; Yin, B.; Coleman, R.E.; DeGrado, T.R.; Landolfo, C.K.; Lowe, J.E.; Annex, B.H.; Landolfo, K.P. Therapeutic angiogenesis in chronically ischemic porcine myocardium, comparative effects of bFGF and VEGF. Ann. Thorac. Surg., 2004, 77, 812-818.
108. Lee, C.H.; Smits, P.C. Vascular growth factors for coronary angiogenesis. J. Interv. Cardiol., 2002, 15, 511-518.
109. Sato, K.; Wu, T.; Laham, R.J.; Johnson, R.B.; Douglas, P.; Li, J.; Sellke, F.W.; Bunting, S.; Simons, M.; Post, M.J. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J. Am. Coll. Cardiol., 2001, 37, 616-623.
110. Kinnaird, T.; Stabile, E.; Burnett, M.S.; Epstein, S.E. Bonemarrow-derived cells for enhancing collateral development, mechanisms, animal data, and initial clinical experiences. Circ. Res., 2004, 95, 354-363.
111. Al-Khaldi, A.; Eliopoulos, N.; Martineau, D.; Lejeune, L.; Lachapelle, K.; Galipeau, J. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene. Ther., 2003, 10, 621-629.
112. Chen, J.; Zhang, Z.G.; Li, Y.; Wang, L.; Xu, Y.X.; Gautam, S.C.; Lu, M.; Zhu, Z.; Chopp, M. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ. Res., 2003, 92, 692-699.
113. Marti, H.H. Erythropoietin and the hypoxic brain. J. Exp. Biol., 2004, 207, 3233-3242.
114. Buemi, M.; Cavallaro, E.; Floccari, F.; Sturiale, A.; Aloisi, C.; Trimarchi, M.; Corica, F.; Frisina, N. The pleiotropic effects of erythropoietin in the central nervous system. J. Neuropathol. Exp. Neurol., 2003, 62, 228-236.
115. Juul, S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr. Suppl., 2002, 91, 36-42.
116. Brines, M.L.; Ghezzi, P.; Keenan, S.; Agnello, D.; de Lanerolle, N.C.; Cerami, C.; Itri, L.M.; Cerami, A. Erythropoietin cross the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. USA, 2000, 97, 10526-10531.
117. Ribatti, D.; Presta, M.; Vacca, A.; Ria, R.; Giuliani, R.; Dell'Era, P.; Nico, B.; Roncali, L.; Dammacco, F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood, 1999, 93, 2627-2636.
118. Nitta, K.; Uchida, K.; Kimata, N.; Honda, K.; Kobayashi, H.; Kawashima, A.; Yumura, W.; Nihei, H. Recombinant human erythropoietin stimulates vascular endothelial growth factor release by glomerular endothelial cells. Eur. J. Pharmacol., 1999, 373, 121-124.
119. Kanda, S.; Miyata, Y.; Kanetake, H. Fibroblast growth factor-2-mediated capillary morphogenesis of endothelial cells requires signals via Flt-1/vascular endothelial growth factor receptor-1, possible involvement of c-Akt. J. Biol. Chem., 2004, 279, 4007-4016.
120. Liu, X.; Zheng, S.X.; Zhou, L.J.; Zhu, X.Z. Basic fibroblast growth factor up-regulates the expression of vascular endothelial growth factor in primary cultured rat astrocytes. Acta Pharmacol. Sin., 2000, 21, 19-22.
121. Cheung, W.M.; Chen, S.F.; Nian, G.M.; Lin, T.N. Induction of angiogenesis related genes in the contralateral cortex with a rat three-vessel occlusion model. Chin. J. Physiol., 2000, 43, 119-124.
122. Ke, L.D.; Shi, Y.X.; Im, S.A.; Chen, X.; Yung, W.K. The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines. Clin. Cancer Res., 2000, 6, 2562-2572.
123. Bian, X.W.; Du, L.L.; Shi, J.Q.; Cheng, Y.S.; Liu, F.X. Correlation of bFGF, FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas. Anal. Quant. Cytol. Histol., 2000, 22, 267-274.
124. Couper, L.L.; Bryant, S.R.; Eldrup-Jorgensen, J.; Bredenberg, C.E.; Lindner, V. Vascular endothelial growth factor increases the mitogenic response to fibroblast growth factor-2 in vascular smooth muscle cells in vivo via expression of fms-like tyrosine kinase-1. Circ. Res., 1997, 81, 932-939.
125. Croll, S.D.; Ransohoff, R.M.; Cai, N.; Zhang, Q.; Martin, F.J.; Wei, T.; Kasselman, L.J.; Kintner, J.; Murphy, A.J.; Yancopoulos, G.D.; Weigand, S.J. VEGF-mediated inflammation precedes angiogenesis in adult brain. Exp. Neurol., 2004, 187, 388-402.
126. Zhao, Q.; Ishibashi, M.; Hiasa, K.; Tan, C.; Takeshita, A.; Egashira, K. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension, 2004, 44, 264-270.
127. Yang, R.; Ogasawara, A.K.; Zioncheck, T.F.; Ren, Z.; He, G.W.; DeGuzman, G.G.; Pelletier, N.; Shen, B.Q.; Bunting, S.; Jin, H. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension, 2002, 39, 815-820.
128. Lafuente, J.V.; Bulnes, S.; Mitre, B.; Riese, H.H. Role of VEGF in an experimental model of cortical micronecrosis. Amino Acids, 2002, 23, 241-245
129. Dobrogowska, D.H.; Lossinsky, A.S.; Tarnawski, M.; Vorbrodt, A.W. Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. J. Neurocytol., 1998, 27, 163-173.
130. Yang, R.; Bunting, S.; Ko, A.; Keyt, B.A.; Modi, N.B.; Zioncheck, T.F.; Ferrara, N.; Jin, H. Substantially attenuated hemodynamic responses to Escherichia coli-derived vascular endothelial growth factor given by intravenous infusion compared with bolus injection. J. Pharmacol. Exp. Ther., 1998, 284, 103-110.
131. Zhao, L.; Zhang, M.M.; Ng, K.Y. Effects of vascular permeability factor on the permeability of cultured endothelial cells from brain capillaries. J. Cardiovasc. Pharmacol., 1998, 32, 1-4.
132. Yang, R.; Thomas, G.R.; Bunting, S.; Ko, A.; Ferrara, N.; Keyt, B.; Ross, J.; Jin, H. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J. Cardiovasc. Pharmacol., 1996, 27, 838-844.
133. Xu, B.; Wu, Y.Q.; Huey, M.; Arthur, H.M.; Marchuk, D.A.; Hashimoto, T.; Young, W.L.; Yang, G.Y. Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain. J. Cereb. Blood Flow Metab., 2004, 24, 237-244.
134. Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983, 219, 983-985.
135. Leung, D.W.; Cachianes, G.; Goeddel, D.V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989, 246, 1306-1309.
136. Manoonkitiwongsa, P.S.; Schultz, R.L.; Whitter, E.F.; Lyden, P.D. Contraindications of VEGF-based therapeutic angiogenesis, Effects on macrophage density and histology of normal and ischemic brains. Vasc. Pharmacol., 2006, 44, 316-325.
137. Manoonkitiwongsa, P.S.; Jackson-Friedman, C.; McMillan, P.J.; Schultz, R.L.; Lyden, P.D. Angiogenesis after stroke is correlated with increased numbers of macrophages, the clean-up hypothesis. J. Cereb. Blood Flow Metab., 2001, 21, 1223-1231.
138. Manoonkitiwongsa, P.S.; Schultz, R.L.; McCreery, D.B.; Whitter, E.F.; Lyden, P.D. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be comprised by angiogenesis. J. Cereb. Blood Flow Metab., 2004, 24, 693-702.
139. Hayashi, T.; Deguchi, K.; Nagotani, S.; Zhang, H.; Sehara, Y.; Tsuchiya, A.; Abe, K. Cerebral ischemia and angiogenesis. Neurovasc. Res., 2006, 3, 119-129.
140. Sun, F.Y.; Guo, X. Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor. J. Neurosci. Res., 2005, 79, 180-184.
141. Ren, J.M.; Finklestein, S.P. Growth factor treatment of stroke. Curr. Drug Targets CNS Neurol. Disord., 2005, 4, 121-125.
142. Svensson, B.; Peters, M.; Konig, H.G.; Poppe, M.; Levkau, B.; Rothermundt, M.; Arolt, V.; Kogel, D.; Prehn, J.H. Vascular endothelial growth factor protects cultured rat hippocampal neurons against hypoxic injury via an antiexcitotoxic, caspaseindependent mechanism. J. Cereb. Blood Flow Metab., 2002, 22, 1170-1175.
143. Matsuzaki, H.; Tamatani, M.; Yamaguchi, A.; Namikawa, K.; Kiyama, H.; Vitek, M.P.; Mitsuda, N.; Tohyama, M. Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity, signal transduction cascades. FASEB J., 2001, 15, 1218-1220.
144. Jin, K.L.; Mao, X.O.; Greenberg, D.A. Vascular endothelial growth factor rescues HN33 neural cells from death induced by serum withdrawal. J. Mol. Neurosci., 2000, 14, 197-203.
145. Sondell, M.; Lundborg, G.; Kanje, M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J. Neurosci., 1999, 19, 5731-5740.
146. Silverman, W.F.; Krum, J.M.; Mani, N.; Rosenstein, J.M. Vascular, glial and neuronal effects of vascular endothelial growth factor in mesencephalic explant cultures. Neuroscience, 1999, 90, 1529-1541.
147. Alon, T.; Hemo, I.; Itin, A.; Pe'er, J.; Stone, J.; Keshet, E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med., 1995, 1, 1024-1028.
148. Fisher, M.; Feuerstein, G.; Howells, D.W.; Hurn, P.D.; Kent, T.A.; Savitz, S.I.; Lo, E.H.; STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke, 2009, 40, 2244-2250.
149. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke, 2001, 32, 1598-1606.
150. Toyama, K.; Honmou, O.; Harada, K.; Suzuki, J.; Houkin, K.; Hamada, H.; Kocsis, J.D. Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. Exp. Neurol., 2009, 216, 47-55.
151. Ataus, S.A.; Onal, M.Z.; Ozdem, S.S.; Locke, K.W.; Balkan, S. The effects of citicoline and lamotrigine alone and in combination following permanent middle cerebral artery occlusion in rats. Int. J. Neurosci., 2004, 114, 183-196.
152. Bradberry, J.C.; Fagan, S.C.; Gray, D.R.; Moon, Y.S. New perspectives on the pharmacotherapy of ischemic stroke. J. Am. Pharm. Assoc., 2004, 44, S46-S56.
153. Sobrado, M.; Lopez, M.G.; Carceller, F.; Garcia, A.G.; Roda, J.M. Combined nimodipine and citicoline reduce infarct size, attenuation apoptosis and increase bcl-2 expression after focal cerebral ischemia. Neuroscience, 2003, 118, 107-113.
154. Nappi, J.; Talbert, R. Dual antiplatelet therapy for prevention of recurrent ischemic events. Am. J. Health Syst. Pharm., 2002, 59, 1723-1735.
155. Schabitz, W.R.; Li, F.; Irie, K.; Sandage, Jr. B.W.; Locke, K.W.; Fisher, M. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Stroke, 1999, 30, 427-431.
156. Gamble, J.R.; Drew, J.; Trezise, L.; Underwood, A.; Parsons, M.; Kasminkas, L.; Rudge, J.; Yancopoulos, G.; Vadas, M.A. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ. Res., 2000, 87, 603-607.
157. Thurston, G.; Rudge, J.S.; Ioffe, E.; Zhou, H.; Ross, L.; Croll, S.D.; Glazer, N.; Holash, J.; McDonald, D.M.; Yancopoulos, G.D. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med., 2000, 6, 460-463.
158. Valable, S.; Montaner, J.; Bellail, A.; Berezowski, V.; Brillault, J.; Ceccehelli, R.; Divoux, D.; Mackenzie, E.T.; Bernaudin, M.; Roussel, S.; Petit, E. VEGF-induced BBB permeability is associated with an MMP-9 activity increase in cerebral ischemia, both effects decreased by Ang-1. J. Cereb. Blood Flow Metab., 2005, 25, 1491-1504.
159. Thurston, G.; Rudge, J.S.; Ioffe, E.; Papadopoulos, N.; Daly, C.; Vuthoori, S.; Daly, T.; Weigand, S.J.; Yancopoulos, G.D. The anti-inflammatory actions of angiopoietin-1. EXS, 2005, 94, 233-245.
160. Papapetropoulos, A.; Fulton, D.; Mahboubi, K.; Kalb, R.G.; O'Connor, D.S.; Li, F.; Altieri, D.C.; Sessa, W.C. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J. Biol. Chem., 2000, 275, 9102-9105.
161. Papapetropoulos, A.; Garcia-Cardena, G.; Dengler, T.J.; Maisonpierre, P.C.; Yancopoulos, G.D.; Sessa, W.C. Direct actions of angiopoietin-1 on human endothelium, evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab. Invest., 1999, 79, 213-223.
162. Greenberg, D.A. Angiogenesis and stroke. Drug News Perspect., 1998, 11, 265-270.
163. Carmeliet, P. Blood vessels and nerves, common signals, pathways and diseases. Nat. Rev. Genet., 2003, 4, 710-720.
164. Yancopoulos, G.D.; Davis, S.; Gale, N.W.; Rudge, J.S.; Wiegand, S.J.; Holash, J. Vascular-specific growth factors and blood vessel formation. Nature, 2000, 407, 242-248.
165. Ferrara, N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat, 1995, 36, 127-137.
166. Thurston, G. Complimentary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage. J. Anat., 2002, 200, 575-580.
167. Fan, Y.; Yang, G.Y. Therapeutic angiogenesis for brain ischemic, a brief review. J. Neuroimmune. Pharmacol., 2007, 2, 284-289.
168. Slevin, M.; Kumar, P.; Gaffney, J.; Kumar, S.; Krupinski, J. Can angiogenesis be exploited to improve stroke outcome? Clin. Sci., 2006, 111, 171-183.
169. Breen, E.C. VEGF in biological control. J. Cell Biochem., 2007, 102, 1358-1367.
170. Nash, A.D.; Baca, M.; Wright, C.; Scotney, P.D. The biology of vascular endothelial growth factor-B (VEGF-B). Pulm. Pharmacol. Ther., 2006, 19, 61-69.
171. Sun, Y.; Jin, K.; Childs, J.T.; Xie, L.; Mao, X.O.; Greenberg, D.A. Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis, evidence from knockout mice and growth factor administration. Dev. Biol., 2006, 289, 329-335.
172. Mould, A.W.; Greco, S.A.; Cahill, M.M.; Tonks, I.D.; Bellomo, D.; Patterson, C.; Zournazi, A.; Nash, A.; Scotney, P.; Hayward, N.K.; Kay, G.F. Transgenic overexpression of vascular endothelial growth factor-B isoforms by endothelial cells potentiates postnatal vessel growth in vivo and in vitro. Circ. Res., 2005, 16, 60-70.
173. Tammela, T.; Enholm, B.; Alitalo, K.; Paavonen, K. The biology of vascular endothelial growth factors. Cardiovasc. Res., 2005, 65, 550-563.
174. Poesen, K.; Lambrechts, D.; Van Damme, P.; Dhondt, J.; Bender, F.; Frank, N.; Bogaert, E.; Claes, B.; Heylen, L.; Verheyen, A.; Raes, K.; Tjwa, M.; Eriksson, U.; Shibuya, M.; Nuydens, R.; Van Den Bosch, L.; Meert, T.; D'Hooge, R.; Sendtner, M.; Robberecht, W.; Carmeliet, P. J. Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration. Neuroscience, 2008, 28, 10451-10459.
175. Zhang, F.; TanTYASSDg, Z.; Hou, X.; Lennartsson, J.; Li, Y.; Koch, A.W.; Scotney, P.; Lee, C.; Arjunan, P.; Dong, L.; Kumar, A.; Rissanen, T.T.; Wang, B.; Nagai, N.; Fons, P.; Fariss, R.; Zhang, Y.; Wawrousek, E.; Tansey, G.; Raber, J.; Fong, G.H.; Ding, H.; Greenberg, D.A.; Becker, K.G.; Herbert, J.M.; Nash, A.; Yla-Herttuala, S.; Cao, Y.; Watts, R.J.; Li, X. VEGF-B is disposable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc. Natl. Acad. Sci. USA, 2009, 106, 6152-6157.
176. Wafai, R.; Tudor, E.M.; Angus, J.A.; Wright, C.E. Vascular effects of FGF-2 and VEGF-B in rabbits with bilateral hind limb ischemia. J. Vasc. Res., 2009, 46, 45-54.
177. Stacker, S.A.; Williams, R.A.; Achen, M.G. Lymphangiogenic growth factors as markers of tumor metastasis. APMIS, 2004, 112,539-549.
178. Makinen, T.; Jussila, L.; Veikkola, T.; Karpanen, T.; Kettunen, M.I.; Pulkkanen, K.J.; Kauppinen, R.; Jackson, D.G.; Kubo, H.; Nishikawa, S.; Yla-Herttuala, S.; Alitalo, K. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med., 2001, 7, 199-205.
179. Veikkola, T.; Jussila, L.; Makinen, T.; Karpanen, T.; Jeltsch, M.; Petrova, T.V.; Kubo, H.; Thurston, G.; McDonald, D.M.; Achen, M.G.; Stacker, S.A.; Alitalo, K. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J., 2001, 20, 1223-1231.
180. Jeltsch, M.; Kaipainen, A.; Joukov, V.; Meng, X.; Lakso, M.; Rauvala, H.; Swartz, M.; Fukumura, D.; Jain, R.K.; Alitalo, K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science, 1997, 276, 1423-1425.
181. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9, 669-676.
182. Carmeliet, P.; Moons, L.; Luttun, A.; Vicenti, V.; Compernolle, V.; De Mol, M.; Wu, Y.; Bono, F.; Devy, L.; Beck, H.; Scholz, D.; Acker, T.; DiPalma, T.; Dewerchin, M.; Noel, A.; Stalmans, I.; Barra, A.; Blacher, S.; Vandendriessche, T.; Ponten, A.; Eriksson, U.; Plate, K.H.; Foidart, J.M.; Schaper, W.; Charnock-Jones, D.S.; Hicklin, D.J.; Herbert, J.M.; Collen, D.; Persico, M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med., 2001, 7, 575-583.
183. Sawano, A.; Takahashi, T.; Yamaguchi, S.; Aonuma, M.; Shibuya, M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ., 1996, 7, 213-231.
184. Oura, H.; Bertoncini, J.; Velasco, P.; Brown, L.F.; Carmeliet, P.; Detmar, M. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood, 2003, 101, 560-567.
185. Heil, M.; Mitnacht-Krauss, R.; Issbrucker, K.; van den Heuvel, J.; Dehio, C.; Schaper, W.; Clauss, M.; Weich, H.A. An engineered heparin-binding form of VEGF-E (hb VEGF-E). Biological effects in vitro and mobilization of precursor cells. Angiogenesis, 2003, 6, 201-211.
186. Shibuya, M. Vascular endothelial growth factor receptor-2, its unique signaling and specific ligand, VEGF-E. Cancer Sci., 2003, 94, 751-756.
187. Meyer, M.; Clauss, M.; Lepple-Wienhues, A.; Waltenberger, J.; Augustin, H.G.; Ziche, M.; Lanz, C.; Buttner, M.; Rziha, H.J.; Dehio, C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J., 1999, 18, 363-374.
188. Ogawa, S.; Oku, A.; Sawano, A.; Yamaguchi, S.; Yazaki, Y.; Shibuya, M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem., 1998, 273, 31273-31282.
189. Kaya, D.; Gursoy-Ozdemir, Y.; Yemisci, M.; Tuncer, N.; Aktan, S.; Dalkara, T. VEGF protects brain against focal ischemia without increasing blood-brain permeability when administered intracerebroventricularly. J. Cereb. Blood Flow Metab., 2005, 25, 1111-1118.
190. Yano, A.; Shingo, T.; Takeuchi, A.; Yasuhara, T.; Kobayashi, K.; Takahashi, K.; Muraoka, K.; Matsui, T.; Miyoshi, Y.; Hamada, H.; Date, I. Encapsulated vascular endothelial growth factor-ecreting cell grafts have neuroprotective and angiogenic effects on focal cerebral ischemia. J. Neurosurg., 2005, 103, 104-114.
191. Hu, M.J.; Liu, Y.; Deng, C.G.; Chang, Y.Q.; Wang, J.N.; Dong, Y.Z. Heat shock protein 70 expression in the brain of rats with cerebral infarction after receiving vascular endothelial growth factor 165 gene therapy. Di Yi Jun Yi Da Xue Xue Bao, 2003, 23, 720-722.
192. Testa, U.; Pannitteri, G.; Condorelli, G.L. Vascular endothelial growth factors in cardiovascular medicine. J. Cardiovasc. Med., 2008, 9, 1190-1221.
193. Ginsberg, M.D.; Busto, R. Combating hyperthermia in acute stroke, a significant clinical concern. Stroke, 1998, 29, 529-534.
194. Koehler, R.C. Large animal models of focal and global ischemia. In: Cerebrovascular Disease, Pathophysiology, Diagnosis and Management; Ginsberg, M.D.; Bogousslavsky, J., Eds.; Blackwell Scientific Publications: Malden, MA, 1998, pp. 36-51.
195. Beaulieu, C.; Busch, E.; Rother, J.; de Crespigny, A.; Hsia, C.J.; Moseley, M.E. Polynitroxyl albumin reduces infarct size in transient focal cerebral ischemia in the rat, potential mechanisms studied by magnetic resonance imaging. J. Cereb. Blood Flow Metab., 1998, 18, 1022-1031.
196. Willing, A.E. Experimental models, help or hindrance. Stroke, 2009, 40, S152-154.
197. Zhang, Z.; Zhang, R.L.; Jiang, Q.; Raman, S.B.; Cantwell, L.; Chopp, M. A new rat model of thrombotic focal cerebral ischemia. J. Cereb. Blood Flow Metab., 1997, 17, 123-135.
198. Broderick, J.P.; Hacke, W. Treatment of acute ischemic stroke, Part I, recanalization strategies. Circulation, 2002,106, 1563-1569.
199. Chan, P.H. Role of oxidants in ischemic brain damage. Stroke, 1996, 27, 1124-1129.
200. Ho, P.W.; Reutens, D.C.; Phan, T.G.; Wright, P.M.; Markus, R.; Indra, I.; Young, D.; Donnan, G.A. Is white matter involved in patients entered into typical trials of neuroprotection? Stroke, 2005, 36, 2742-2744.
201. Ransom, B.R.; Stys, P.K.; Waxman, S.G. The pathophysiology of anoxic injury in central nervous system white matter. Stroke, 1990, 21, III52-III57
202. Beck, H.; Acker, T.; Wiessner, C.; Allegrini, P.R.; Plate, K.H. Expression of angiopoietin-1, angiopoietin-2, and tie receptors after middle cerebral artery occlusion in the rat. Am. J. Pathol., 2000, 157, 1473-1483.
203. Alkayed, N.J.; Harukuni, I.; Kimes, A.S.; London, E.D.; Traystman, R.J.; Hurn, P.D. Gender-linked brain injury in experimental stroke. Stroke, 1998, 29, 159-165.
204. Toung, T.J.; Traystman, R.J.; Hurn, P.D. Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke, 1998, 29, 1666-1670.
205. Yager, J.Y.; Thornhill, J.A. The effect of age on susceptibility to hypoxic-ischemic brain damage. Neurosci. Biobehav. Rev., 1997, 21, 167-174.
206. Leys, D.; Woimant, F.; Ferrieres, J.; Bauters, C.; Touboul, P.J.; Guerillot, M.; Herrmann, M.A.; Priollet, P. Detection and management of associated atherothrombotic locations in patients with a recent atherothrombotic ischemic stroke, results of the DETECT survey. Cerebrovasc. Dis., 2006, 21, 60-66.
207. Fang, X.H.; Tang, Z.; Zimmer, Z.; Xiang, M.J.; Kaneda, T. Effects and trends of stroke and life expectancy among older adults--from 1990s to 2000s. Zhonghua Liu Xing Bing Xue Za Zhi, 2009, 30, 105-109.
208. Schaller, B. Influence of age on stroke and preconditioning-induced ischemic tolerance in the brain. Exp. Neurol., 2007, 205, 9-19.
209. Uchino, K.; Billheimer, D.; Cramer, S.C. Entry criteria and baseline characteristics predict outcome in acute stroke trials. Stroke, 2001, 32, 909-916.
210. Sutherland, G.R.; Dix, G.A.; Auer, R.N. Effect of age in rodent models of focal and forebrain ischemia. Stroke, 1996, 27, 1663-1667.
211. Shapira, S.; Sapir, M.; Wengier, A.; Grauer, E.; Kadar, T. Aging has a complex effect on a rat model of ischemic stroke. Brain Res., 2002, 925, 148-158.
212. Magnusson, K.R.; Nelson, S.E.; Young, A.B. Age-related changes in the protein expression of subunits of the NMDA receptor. Brain Res. Mol. Brain Res., 2002, 99, 40-45.
213. Yao, H.; Sadoshima, S.; Ooboshi, H.; Sato, Y.; Uchimura, H.; Fujishima, M. Age-related vulnerability to cerebral ischemia in spontaneously hypertensive rats. Stroke, 1991, 22, 1414-1418.
214. Jin, K.; Minami, M.; Xie, L.; Sun, Y.; Mao, X.O.; Wang, Y.; Simon, R.P.; Greenberg, D.A. Ischemia-induced neurogenesis is preserved but reduced in the aged rodent brain. Aging Cell, 2004, 3, 373-377.
215. Corbett, D.; Nurse, S.; Colbourne, F. Hypothermic neuroprotection. A global ischemia study using 18- to 20-month-old gerbils. Stroke, 1997, 28, 2238-2242.
216. Bell, M.A.; Ball, M.J. Morphometric comparison of hippocampal microvasculature in ageing and demented people, diameters and densities. Acta Neuropathol., 1981, 53, 299-318.
217. Prado, R.; Ginsberg, M.D.; Dietrich, W.D.; Watson, B.D.; Busto, R. Hyperglycemia increases infarct size in collaterally perfused but not end-arterial vascular territories. J. Cereb. Blood Flow Metab., 1988, 8, 186-192.
218. Kannel, W.B.; McGee, D.L. Diabetes and cardiovascular disease. JAMA, 1979, 241, 2035-2038.
219. Oppenheimer, S.M.; Hoffbrand, B.I.; Oswald, G.A.; Yudkin, J.S. Diabetes mellitus and early mortality from stroke. Br. Med. J., 1985, 291, 1014-1015.
220. Pulsinelli, W.A, Levy, D.E.; Sigsbee, B.; Scherer, P.; Plum, F. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am. J. Med., 1983, 74, 540-544.
221. Fuller, J.H.; Shipley, M.J.; Rose, G.; Jarrett, R.J.; Keen, H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia, the Whitehall study. Br. Med. J., 1983, 287, 867-870.
222. Asplund, K.; Hagg, E.; Helmers, C.; Lithner, F.; Strand, T.; Wester, P.O. The natural history of stroke in diabetic patients. Acta Med. Scand., 1980, 207, 417-424.
223. Kushner, M.; Nencini, P.; Reivich, M.; Rango, M.; Jamieson, D.; Fazekas, F.; Zimmerman, R.; Chawluk, J.; Alavi, A.; Alves, W. Relation of hyperglycemia early in ischemic brain infarction to cerebral anatomy, metabolism, and clinical outcome. Ann. Neurol., 1990, 28, 129-135.
224. Woo, E.; Chan, Y.W.; Yu, Y.L.; Huang, C.Y. Admission glucose level in relation to mortality and morbidity outcome in 252 stroke patients. Stroke, 1988, 19, 185-191.
225. Berger, L.; Hakim, A.M. The association of hyperglycemia with cerebral edema in stroke. Stroke, 1986, 17, 865-871.
226. Candelise, L.; Landi, G.; Orazio, E.N.; Boccardi, E. Prognostic significance of hyperglycemia in acute stroke. Arch. Neurol., 1985, 42, 661-663.
227. Zasslow, M.A.; Pearl, R.G.; Shuer, L.M.; Steinberg, G.K.; Lieberson, R.E.; Larson, C.P.; Jr. Hyperglycemia decreases acute neuronal ischemic changes after middle cerebral artery occlusion in cats. Stroke, 1989, 20, 519-523.
228. Adams, H.P.; Olinger, C.P.; Marler J.R.; Biller, J.; Brott, T.G.; Barson, W.G.; Banwart, K. Comparison of admission serum glucose concentration with neurologic outcome in acute cerebral infarction. A study in patients naloxone. Stroke, 1988, 19, 455-458.
229. Power, M.J.; Fullerton, K.J.; Stout, R.W. Blood glucose and prognosis of acute stroke. Age Ageing, 1988, 17, 164-170.
230. Ginsberg, M.D.; Prado, R.; Dietrich, W.D.; Busto, R.; Watson, B.D. Hyperglycemia reduces the extent of cerebral infarction in rats. Stroke, 1987, 18, 570-574.
231. Cox, N.H.; Lorains, J.W. The prognostic value of blood glucose and glycosylated haemoglobin estimation in patients with stroke. Postgrad. Med. J., 1986, 62, 7-10.
232. Duverger, D.; MacKenzie, E.T. The quantification of cerebral infarction following focal ischemia in the rat, influence of strain, arterial pressure, blood glucose concentration, and age. J. Cereb. Blood Flow Metab., 1988, 8, 449-461.
233. de Courten-Myers, G.; Myers, R.E.; Schoolfield, L. Hyperglycemia enlarges infarct size in cerebrovascular occlusion in cats. Stroke, 1988, 19, 623-630.
234. Brint, S.; Jacewicz, M.; Kiessling, M.; Tanabe, J.; Pulsinelli, W. Focal brain ischemia in the rat, methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. J. Cereb. Blood Flow Metab., 1988, 8, 474-485.
235. Gordon, T.; Kannel, W.B. Predisposition to atherosclerosis in the head, heart, and legs. The Framingham study. JAMA, 1972, 221, 661-666.
236. Kannel, W.B.; Wolf, P.A.; Verter, J.; McNamara, P.M. Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. JAMA, 1970, 214, 301-310.
237. Chapman, J.M.; Reeder, L.G.; Borun, E.R.; Clark, V.A.; Coulson, A.H. Epidemiology of vascular lesions affecting the central nervous system, the occurrence of strokes in a sample population under observation for cardiovascular disease. Am. J. Public Health Nations Health, 1966, 56, 191-201.
238. Goodkin, G. Mortality factors in diabetes. A 20 year mortality study. J. Occup. Med., 1976, 17, 716-721.
239. Laham, R.J.; Li, J.; Tofukuji, M.; Post, M.; Simons, M.; Sellke, F.W. Spatial heterogeneity in VEGF-induced vasodilation, VEGF dilates microvessels but not epicardial and systemic arteries and veins. Ann. Vasc. Surg., 2003, 17, 245-252.
240. Yang, R.; Bunting, S.; Jin, H. Effects of VEGF on hemodynamics and cardiac function, characterization and mechanisms. IDrugs, 2000, 3, 1346-1352.
241. Lopez, J.J.; Laham, R.J.; Carrozza, J.P.; Tofukuji, M.; Sellke, F.W.; Bunting, S.; Simons, M. Hemodynamic effects of intracoronary VEGF delivery, evidence of tachyphylaxis and NO dependence of response. Am. J. Physiol., 1997, 273, H1317-H1323.
242. Hariawala, M.D.; Horowitz, J.R.; Esakof, D.; Sheriff, D.D.; Walter, D.H.; Keyt, B.; Isner, J.M.; Symes, J.F. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in procine hearts. J. Surg. Res., 1996, 63, 77-82.
243. Sellke, F.W.; Wang, S.Y.; Stamler, A.; Lopez, J.J.; Li, J.; Simons, M. Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am. J. Physiol., 1996, 271, H713-H720.
244. Horowitz, J.R.; Rivard, A.; van der Zee, R.; Hariawala, M.; Sheriff, D.D.; Esakof, D.D.; Chaudhry, G.M.; Symes, J.F.; Isner, J.M. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 2793-2800.
245. van der Zee, R.; Murohara, T.; Luo, Z.; Zollman, F.; Passseri, J.; Lekutat, C.; Isner, J.M. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation, 1997, 95, 1030-1037.
246. Ku, D.D.; Zaleski, J.K.; Liu, S.Y.; Brock, T.A. Vascular endothelial growth factor induced EDRF-dependent relaxation in coronary arteries. Am. J. Physiol., 1993, 256, H586-H592.
247. Deguchi, Y.; Naito, T.; Yuge, T.; Furukawa, A.; Yamada, S.; Pardridge, W.M.; Kimura, R. Blood-brain barrier transport of 125Ilabeled basic fibroblast growth factor. Pharm. Res., 2000, 17, 63-69.
248. Bogousslavsky, J.; Victor, S.J.; Salinas, E.O.; Pallay, A.; Donnan, G.A.; Fieschi, C.; Kaste, M.; Orgogonzo, J.M.; Chamorro, A.; Desmet, A. Fiblast (trafermin) in acute stroke, results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc. Dis., 2002, 14, 239-251.
249. Pardridge, W.M. Molecular biology of the blood-brain barrier. Mol. Biotechnol., 2005, 30, 57-70.
250. Schlachetzki, F.; Zhang, Y.; Boado, R.J.; Pardridge, W.M. Gene therapy of the brain, the trans-vascular approach. Neurology, 2004, 62, 1275-1281.
251. Juul, S.E.; McPherson, R.J.; Farrell, F.X.; Jolliffe, L.; Ness, D.J.; Gleason, C.A. Erythropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol. Neonate., 2004, 85, 138-144.
252. Coleman, T.; Brines, M. Science review, recombinant human erythropoietin in critical illness, a role beyond anemia? Crit. Care, 2004, 8, 337-341.
253. Grasso, G.; Sfacteria, A.; Cerami, A.; Brines, M. Erythropoietin as a tissue-protective cytokine in brain injury, what do we know and where do we go? Neuroscientist, 2004, 10, 93-98.
254. Banks, W.A.; Jumbe, N.L.; Farrell, C.L.; Niehoff, M.L.; Heatherington, A.C. Passage of erythropoietic agents across the blood-brain barrier, a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur. J. Pharmacol., 2004, 505, 93-101.
255. Wiessner, C.; Allegrini, P.R.; Ekatodramis, D.; Jewell, U.R.; Stallmach, T.; Gassmann, M. Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J. Cereb. Blood Flow Metab., 2001, 21, 857-864.
256. Yokomaku, Y.; Sugimoto, T.; Kume, S.; Araki, S.; Isshiki, K.; Chin-Kanasaki, M.; Sakaguchi, M.; Nitta, N.; Haneda, M.; Koya, D.; Uzu, T.; Kashiwagi, A. Asialoerythropoietin prevents contrastinduced nephropathy. J. Am. Soc. Nephrol., 2008, 19, 321-328.
257. Okada, T.; Sawada, T.; Kubota, K. Asialoerythropoietin has strong renoprotective effects against ischemia-reperfusion injury in a murine model. Transplantation, 2007, 84, 504-510.
258. Erbayraktar, S.; Grasso, G.; Sfacteria, A.; Xie, Q.W.; Coleman, T.; Kreilgaard, M.; Torup, L.; Sager, T.; Erbayraktar, Z.; Gokmen, N.; Yilmaz, O.; Ghezzi, P.; Villa, P.; Fratelli, M.; Casagrande, S.; Leist, M.; Helboe, L.; Gerwein, J.; Christensen, S.; Geist, M.A.; Pederson, L.O.; Cerami-Hand, C.; Wuerth, J.P.; Cerami, A.; Brines, M. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. USA, 2003, 100, 6741-6746.
259. Harrigan, M.R.; Ennis, S.R.; Sullivan, S.E.; Keep, R.F. Effects of intraventricular infusion of vascular endothelial growth factor on cerebral blood flow, edema, and infarct volume. Acta Neurochir. (Wien), 2003, 145, 49-53.
260. Tilton, R.G.; Chang, K.C.; LeJeune, W.S.; Stephan, C.C.; Broc, T.A.; Williamson, J.R. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest. Ophthalmol. Vis. Sci., 1999, 40, 689-696.
261. Hayashi, T.; Abe, K.; Itoyama, Y. Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia. J. Cereb. Blood Flow Metab., 1998, 18, 887-895.
262. Al Sabti, H. Therapeutic angiogenesis in cardiovascular disease. J. Cardiothorac. Surg., 2007, 2, 49.
263. Wang, Y.Q.; Guo, X.; Qiu, M.H.; Feng, X.Y.; Sun, F.Y. VEGF overexpression enhances striatal neurogenesis in brain of adult rat after a transient middle cerebral artery occlusion. J. Neurosci. Res., 2007, 85, 73-82.
264. Stiver, S.I.; Tan, X.; Brown, L.F.; Hedley-Whyte, E.T.; Dvorak, H.F. VEGF-A angiogenesis induces a stable neovasculature in adult murine brain. J. Neuropathol. Exp. Neurol., 2004, 63, 841-855.
265. Fujii, H.; Sun, Z.; Li, S.H.; Wu, J.; Fazel, S.; Weisel, R.D.; Rakowski, H.; Lindner, J.; Li, R.K. Ultrasound-targeted gene delivery induces angiogenesis after a myocardial infarction in mice. JACC Cardiovasc. Imaging, 2009, 2, 869-879.
266. Korpanty, G.; Chen, S.; Shohet, R.V.; Ding, J.; Yang, B.; Frenkel, P.A.; Grayburn, P.A. Targeting of VEGF-mediated angiogenesis to rat myocardium using ultrasonic destruction of microbubbles. Gene. Ther., 2005, 12, 1305-1312.
267. Yang, J.; Song, C.; Sun, H.; Wu, L.; Tang, L.; Leng, X.; Wang, P.; Xu, Y.; Li, Y.; Guan, H. Polymeric nanoparticles with therapeutic gene for gene therapy, I. Preparation and in vivo gene transfer study. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, 2005, 22, 438-442.
268. Zhigang, W.; Zhiyu, L.; Haitao, R.; Hong, R.; Qunxia, Z.; Ailong, H.; Qi, L.; Chunjing, Z.; Hailin, T.; Lin, G.; Mingli, P.; Shiyu, P. Ultrasound-mediated microbubble destruction enhances VEGF gene delivery to the infarcted myocardium in rats. Clin. Imaging, 2004, 28, 395-398.
269. Lee, M.; Rentz, J.; Bikram, M.; Han, S.; Bull, D.A.; Kim, S.W. Hypoxia-inducible VEGF gene delivery to ischemic myocardium using water-soluble lipopolymer. Gene Ther., 2003, 10, 1535-1542.
270. Kang, S.W.; Lim, H.W.; Seo, S.W.; Jeon, O.; Lee, M.; Kim, B.S. Nanosphere-mediated delivery of vascular endothelial growth factor gene for therapeutic angiogenesis in mouse ischemic limbs. Biomaterials, 2008, 29, 1109-1117.
271. Huang, M.; Vitharana, S.N.; Peek, L.J.; Coop, T.; Berkland, C. Polyelectrolyte complexes stabilize and controllably release vascular endothelial growth factor. Biomacromolecules, 2007, 8, 1607-1614.
272. Ye, L.; Haider, H.; Tan, R.; Toh, W.; Law, P.K.; Tan, W.; Su, L.; Zhang, W.; Ge, R.; Zhang, Y.; Lim, Y.; Sim, E.K. Transplantation of nanoparticle transfected skeletal myoblasts overexpressing vascular endothelial growth factor-165 for cardiac repair. Circulation, 2007, 116, 113-120.
273. Yi, F.; Wu, H.; Jia, G.L.; Guo, W.Y.; Lu, A.L.; Wang, H.C.; Zhang, R.Q. Effect of nanoparticle with vascular endothelial growth factor gene transferred into ischemic myocardium, experiment with rabbits. Zhonghua Yi Xue Za Zhi, 2006, 86, 510-514.
274. Siddiqui, A.J.; Blomberg, P.; Wardell, E.; Hellgren, I.; Eskandarpour, M.; Islam, K.B.; Sylven, C. Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium. Biochem. Biophys. Res. Commun., 2003, 310, 1002-1009.
275. Su, H.; Arakawa-Hoyt, J.; Kan, Y.W. Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc. Natl. Acad. Sci. USA, 2002, 99, 9480-9485.
276. Yockman, J.W.; Choi, D.; Whitten, M.G.; Chang, C.W.; Kastenmeier, A.; Erickson, H.; Albanil, A.; Lee, M.; Kim, S.W.; Bull, D.A. Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct. Gene. Ther., 2009, 16, 127-135.
277. Mataveli, F.D.; Han, S.W.; Nader, H.B.; Mendes, A.; Kanishiro, R.; Tucci, P.; Lopes, A.C.; Baptista-Silva, J.C.; Marolla, A.P.; de Carvalho, L.P.; Denapoli, P.M.; Pinhal, M.A. Long-term effects for acute phase myocardial infarct VEGF165 gene transfer cardiac extracellular matrix remodeling. Growth Factors, 2009, 27, 22-31.
278. Li, Z.; Wang, R.; Li, S.; Wei, J.; Zhang, Z.; Li, G.; Dou, W.; Wei, Y.; Feng, M. Intraventricular pre-treatment with rAAV-VEGF induces intracranial hypertension and aggravates ischemic injury at the early stage of transient focal cerebral ischemia in rats. Neurol. Res., 2008, 30, 868-875.
279. Chu, K.; Jung, K.H.; Kim, S.J.; Lee, S.T.; Kim, J.; Park, H.K.; Song, E.C.; Kim, S.U.; Kim, M.; Lee, S.K.; Roh, J.K. Transplantation of human neural stem cells protect against ischemia in a preventive mode via hypoxia-inducible factor-1alpha stabilization in the host brain. Brain Res., 2008, 1207, 182-192.
280. Veizovic, T.; Beech, J.S.; Stroemer, P.; Watson, W.P.; Hodges, H. Resolution of stroke deficits following contralateral grafts of conditionally immortal neuroepithelial stem cells. Stroke, 2001, 32, 1012-1019.
281. Chen, J.; Sanberg, P.R.; Li, Y.; Wang, L.; Lu, M.; Willing, A.E.; Sanchez-Ramos, J.; Chopp, M. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke, 2001, 32, 2682-2688.
282. Toda, H.; Takahashi, J.; Iwakami, N.; Kimura, T.; Hoki, S.; Mozumi-Kitamura, K.; Ono, S.; Hashimoto, N. Grafting neural stem cells improved the impaired spatial recognition in ischemic rats. Neurosci. Lett., 2001, 316, 9-12.
283. Abe, K. Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury. J. Cereb. Blood Flow Metab., 2000, 20, 1393-1408.
284. Park, K.I. Transplantation of neural stem cells, cellular & gene therapy for hypoxic-ischemic brain injury. Yonsei Med. J., 2000, 41, 825-835.
285. Fukunaga, A.; Uchida, K.; Hara, K.; Kuroshima, Y.; Kawase, T. Differentiation and angiogenesis of central nervous system stem cells implanted with mesenchyme into ischemic rat brain. Cell Transplant, 1999, 8, 435-441.
286. Nishino, H.; Borlongan, C.V. Restoration of function by neural transplantation in the ischemic brain. Prog. Brain Res., 2000, 127, 461-476.
287. Oyamada, N.; Itoh, H.; Sone, M.; Yamahara, K.; Miyashita, K.; Park, K.; Taura, D.; Inuzuka, M.; Sonoyama, T.; Tsujimoto, H.; Fukunaga, Y.; Tamura, N.; Nakao, K. Transplantation of vascular cells derived from human embryonic stem cells contributes to vascular regeneration after stroke in mice. J. Transl. Med., 2008, 6, 54.
288. Chen, J.; Chopp, M. Neurorestorative treatment of stroke, cell and pharmacological approaches. NeuroRx, 2006, 3, 466-473.
289. Lee, H.J.; Kim, K.S.; Park, I.H.; Kim, S.U. Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS One, 2007, 2, e156.
290. Schanzer, A.; Wachs, F.P.; Wilhelm, D.; Acker, T.; Cooper-Kuhn, C.; Beck, H.; Winkler, J.; Aigner, L.; Plate, K.H.; Kuhn, H.G. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol., 2004, 14, 237-248.
291. Ozawa, C.R.; Banfi, A.; Glaze, N.L.; Thurston, G.; Springer, M.L.; Kraft, P.E.; McDonald, D.M.; Blau, H.M. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J. Clin. Invest., 2004, 113, 516-527.
292. Abumiya, T.; Yokota, C.; Kuge, Y.; Minematsu, K. Aggravation of hemorrhagic transformation by early intraarterial infusion of lowdose vascular endothelial growth factor after transient focal cerebral ischemia in rats. Brain Res., 2005, 1049, 95-103.
293. Proescholdt, M.A.; Heiss, J.D.; Walbridge, S.; Muhlhauser, J.; Capogrossi, M.C.; Oldfield, E.H.; Merrill, M.J. Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J. Neuropathol. Exp. Neurol., 1999, 58, 613-627.
294. Tolentino, M.J.; Miller, J.W.; Gragoudas, E.S.; Jakobiec, F.A.; Flynn, E.; Chatzistefanou, K.; Ferrara, N.; Adamis, A.P. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology, 1996, 103, 1820-1828.
295. Tsuchihashi, S.; Ke, B.; Kaldas, F.; Flynn, E.; Busuttil, R.W.; Briscoe, D.M.; Kupiec-Weglinski, J.W. Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury. Am. J. Pathol., 2006, 168, 695-705.
296. Knowles, H.; Leek, R.; Harris, A.L. Macrophage infiltration and angiogenesis in human malignancy. Novartis Found. Symp., 2004, 256, 189-200.
297. Cramer, T.; Yamanishi, Y.; Clausen, B.E.; Forster, I.; Pawlinski, R.; Mackman, N.; Haase, V.H.; Jaenisch, R.; Corr, M.; Nizet, V.; Firestein, G.S.; Gerber, H.P.; Ferrara, N.; Johnson, R.S. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell, 2003, 112, 645-657.
298. Madjdpour, C.; Jewell, U.R.; Kneller, S.; Ziegler, U.; Schwendener, R.; Booy, C.; Klausli, L.; Pasch, T.; Schimmer, R.C.; Beck-Schimmer, B. Decreased alveolar oxygen induces lung inflammation. Am. J. Physiol. Lung Cell Mol. Physiol., 2003, 284, L360-367.
299. Burke, B.; Tang, N.; Corke, K.P.; Tazzyman, D.; Ameri, K.; Wells, M.; Lewis, C.E. Expression of HIF-1alpha by human macrophages, implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J. Pathol., 2002,196, 204-212.
300. Sandau, K.B.; Fandrey, J.; Brune, B. Accumulation of HIF-1alpha under the influence of nitric oxide. Blood, 2001, 97, 1009-1015.
301. Bingle, L.; Lewis, C.E.; Corke, K.P.; Reed, M.W.; Brown, N.J. Macrophages promote angiogenesis in human breast tumour spheroids in vivo. Br. J. Cancer, 2006, 94, 101-107.
302. Abbott, N.J. Inflammatory mediators and modulation of bloodbrain barrier permeability. Cell Mol. Neurobiol., 2000, 20, 131-147.
303. Petty, M.A.; Lo, E.H. Junctional complexes of the blood-brain barrier, permeability changes in neuroinflammation. Prog. Neurobiol., 2002, 68, 311-323.
304. Morrissey, S.P.; Stodal, H.; Zettl, U.; Simonis, C.; Jung, S.; Kiefer, R.; Lassmann, H.; Hartung, H.P.; Haase, A.; Toyka, K.V. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema. Brain, 1996, 119, 239-248.
305. Green, A.R. Protecting the brain, the search for a clinically effective neuroprotective drug for stroke. Crit. Rev. Neurobiol., 2004, 16, 91-97.
306. Kawai, K.; Takahashi, H.; Ikuta, F. Ultracytochemical study of capillary Ca2+-ATPase activity in brain edema. Acta Neuropathol., 1989, 77, 449-454.
307. Betz, A.L.; Goldstein, G.W. Specialized properties and solute transport in brain capillaries. Annu. Rev. Physiol., 1986, 48, 241-250.
308. Eisenberg, H.M.; Suddith, R.L. Cerebral vessels have the capacity to transport sodium and potassium. Science, 1979, 206, 1083-1085.
309. Katzman, R. Maintenance of a constant brain extracellular potassium. Fed. Proc., 1976, 35, 1244-1247.
310. Castejón, O.J.; Castejón, H.V.; Zavala, M.; Sánchez, M.E.; Díaz, M. A light and electron microscopic study of oedematous human cerebral cortex in two patients with post-traumatic seizures. Brain Inj., 2002, 16, 331-346.
311. Lu, C.H. A light and electron-microscopic study of epileptogenic discharge focus in temporal lobe epilepsy. Zhonghua Bing Li Xue Za Zhi, 1991, 20, 198-200.
312. Lee, H.; Kim, J.M.; Kim, H.J.; Lee, I.; Chang, N. Folic acid supplementation can reduce the endothelial damage in rat brain microvasculature due to hyperhomocysteinemia. J. Nutr., 2005, 135, 544-548.
313. Kipar, A.; Hetzel, U.; Armien, A.G.; Baumgartner, W. Bilateral focal cerebral angiomatosis associated with nervous signs in a cat. Vet. Pathol., 2001, 38, 350-353.
314. Frank, R.N.; Dutta, S.; Frank, S.E. Cerebral cortical capillary basement membrane thickening in galactosaemic rats. Diabetologia, 1987, 30, 739-744.
315. Mancardi, G.L.; Perdelli, F.; Rivano, C.; Leonardi, A.; Bugiani, O. Thickening of the basement membrane of cortical capillaries in Alzheimer's disease. Acta Neuropathol., 1980, 49, 79-83.